Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- Options Strategies & the Zacks Rank
- AWS 5/21: The Beginning of the End for QE
- PFP 5/21: Below the Surface
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| FEDERAL MOGU | FDML | 5.95% |
| RADIANT LOGI | RLGT | 4.26% |
| NEW ORIENTAL | EDU | 3.73% |
| NATUS MEDICA | BABY | 3.44% |
| ADDUS HOMECA | ADUS | 2.48% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Sanofi’s ( SNY - Analyst Report ) vaccines division, Sanofi Pasteur, recently announced that it has begun shipping Fluzone vaccine for the 2012-2013 influenza (flu) season. More than 60 million doses of seasonal influenza vaccine will be supplied to US health care providers during the initial phase of shipment.
The company believes that the early shipment of Fluzone vaccine will enable US health care providers to start immunization and also mitigate their concerns related to the supply of vaccines.
Sanofi announced that in the 2012-2013 influenza season, Fluzone will address two new virus strains. Additionally, the company has developed a new syringe cap for Fluzone, which does not contain latex, making it usable in individuals with latex allergy.
Fluzone will be available in three formulations, namely Fluzone vaccine, Fluzone high-dose vaccine and Fluzone intradermal vaccine. Fluzone vaccine has been in the market for more than 40 years and is the only US Food and Drug Administration (FDA) approved flu vaccine available for 6-month-old children. Fluzone high-dose vaccine, available since 2010, is specifically formulated for individuals above 65 years.
In May 2011, Fluzone intradermal vaccine was approved by the FDA for use in individuals between 18 to 64 years of age. The ultra-fine needle makes Fluzone intradermal vaccine convenient and easy to administer.
Apart from the above mentioned formulations, Sanofi also has a candidate, Fluzone QIV, a quadrivalent vaccine for the prevention of influenza caused by two type A and two type B strains in late stage development. We note that in March 2012, AstraZeneca ( AZN - Analyst Report ) had announced the US approval of FluMist Quadrivalent for the prevention of influenza caused by two type A and two type B strains. FluMist Quadrivalent marked the first approval of a four-strain influenza vaccine by the FDA.
Sanofi possesses one of the world’s leading vaccine operations, with total vaccines sales of €617 million in the first quarter of 2012. The company’s portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines and travel and endemic vaccines. Sanofi also has a strong position in both seasonal and pre-pandemic influenza vaccines.
Our Recommendation
We expect Sanofi to continue containing operating costs in order to increase earnings in the face of weakening sales of some of its key drugs. We also expect the company to pursue bolt on acquisitions. We are pleased with the company’s efforts to develop its pipeline.
We currently have a Neutral recommendation on Sanofi. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
Read the full reports :
Analyst Report on SNY
Analyst Report on AZN